

# Myotonic Dystrophy

Masanori P. Takahashi • Tsuyoshi Matsumura  
Editors

# Myotonic Dystrophy

Disease Mechanism, Current Management  
and Therapeutic Development



Springer

*Editors*

Masanori P. Takahashi  
Department of Functional Diagnostic  
Science  
Osaka University Graduate School  
of Medicine  
Osaka  
Japan

Tsuyoshi Matsumura  
Department of Neurology  
National Hospital Organization Toneyama  
National Hospital  
Osaka  
Japan

ISBN 978-981-13-0507-8      ISBN 978-981-13-0508-5 (eBook)  
<https://doi.org/10.1007/978-981-13-0508-5>

Library of Congress Control Number: 2018957705

© Springer Nature Singapore Pte Ltd. 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.  
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

# Preface

Myotonic dystrophy (DM) is an uncharacteristic form of muscular dystrophy. Despite being a type of muscular dystrophy, the distribution of the affected muscles in DM greatly differs from that of general muscle disorders, which usually affect proximal muscles. The myotonic phenomenon, from which the disease's name is derived, is another cardinal feature. In addition, this condition not only involves the skeletal muscles, but also affects various organs throughout the body. This makes the overall clinical features of individual patients difficult to detect even for neuro-muscular specialists. However, the multi-organ nature of the condition means that clinicians from various medical specialties may encounter it. Furthermore, patients are sometimes unaware of their symptoms and problems, which may prevent them from receiving appropriate care and lead to unexpected complications.

Along with other forms of muscular dystrophy, the understanding of DM pathology has greatly advanced since the discovery of its responsible genes. In 1992, the first genetic cause was identified as an abnormal expansion of CTG repeats located at the 3'-untranslated region of the *DMPK* gene. It was subsequently revealed that the second type of DM, DM2, is caused by the similar abnormal expansion of CCTG repeats located in intron 1 of the *CNBP* gene. The finding that similar clinical feature was caused by abnormal repeats in the untranslated region of two different genes, and also observed in experimental animals that expressed expanded repeats, has led to the notion that DM is caused by abnormal RNA. It was further shown that disruption of normal RNA regulation (splicing) in various genes occurs in DM, leading to the failure of multiple organs, even though the disease is caused by only one gene. Such deeper understanding of the underlying disease mechanisms prompted the therapeutic development and clinical trials that are currently being planned and implemented.

In the era of translational medicine, awareness of the importance of understanding DM and establishing a standardized approach to medical care has increased. It is essential to understand the burden and natural history of the disease and to accurately evaluate the effects of intervention. Furthermore, a comprehensive evaluation of therapeutic efficacy and adverse effects would become considerably difficult if the complications are not accurately recognized and addressed during routine

clinical practice. An accurate understanding of the overall picture of DM is required for both determining what is the optimal current strategy and how we can expand the therapeutic armamentarium in the future.

In Japan, a multidisciplinary approach to muscular dystrophy management has been in place for more than half a century. Clinical research has been extensively carried out at a specialized ward established at the National Hospitals with central involvement of the research consortium supported by the Ministry of Health, Labour and Welfare. As a result of this multidisciplinary approach, which includes respiratory and myocardial protection therapy, patients with Duchenne muscular dystrophy have experienced a marked improvement in their survival prognoses and ability to carry out their daily activities. While extensive clinical research on DM has also been conducted, awareness of its results by overseas audiences is low since most of them are reported in Japanese.

We believe that it is timely that a book by 13 Japanese experts that covers the results of clinical research on DM in Japan and the latest insights regarding disease mechanism, functional impairment, and disorders of various organs be published. We would like to express our deep appreciation of the authors as well as other colleagues and collaborators who contributed to the publishing of this book and hope that it will help clinicians and researchers to acquire a more comprehensive understanding of DM.

Finally, we would like to mention that many of the authors of this book have been mentored by the late Dr. Mitsuru Kawai, the former director of NHO Higashisaitama National Hospital, via the aforementioned research groups and similar academic activities. He was a great clinician and also an excellent mentor of ours. He translated *Myotonic Dystrophy* by Professor Peter Harper for Japanese patients and their families. He always taught us to keep exploring what we can do for patients as clinicians. Dr. Kawai's passing in 2016 was a huge loss to the Japanese muscular dystrophy healthcare community. It is our mission to continue his work through our consistent efforts, and it is in Dr. Kawai's memory that we would like to offer this book with our thoughts and gratitude.

Osaka, Japan  
Osaka, Japan  
February 2018

Tsuyoshi Matsumura  
Masanori P. Takahashi

# Contents

<b>1</b>	<b>Genetics of Myotonic Dystrophy</b> .....	<b>1</b>
	Tohru Matsuura	
<b>2</b>	<b>Molecular Mechanisms of Myotonic Dystrophy: RNA-Mediated Pathogenesis and RNA-Binding Proteins</b> .....	<b>19</b>
	Yoshihiro Kino, Jun-ichi Satoh, and Shoichi Ishiura	
<b>3</b>	<b>Clinical Features of Skeletal Muscle and Their Underlying Molecular Mechanism</b> .....	<b>45</b>
	Masanori P. Takahashi	
<b>4</b>	<b>Cardiac Involvements in Myotonic Dystrophy</b> .....	<b>63</b>
	Hideki Itoh and Takuhisa Tamura	
<b>5</b>	<b>Clinical Features of the Central Nervous System</b> .....	<b>77</b>
	Haruo Fujino, Shugo Suwazono, and Yuhei Takado	
<b>6</b>	<b>Brain Pathology in Myotonic Dystrophy</b> .....	<b>95</b>
	Yasushi Iwasaki	
<b>7</b>	<b>Molecular Defects in the DM Central Nervous System</b> .....	<b>115</b>
	Takashi Kimura	
<b>8</b>	<b>Respiratory Feature in Myotonic Dystrophy</b> .....	<b>133</b>
	Satoshi Kuru	
<b>9</b>	<b>Glucose Intolerance in Myotonic Dystrophy</b> .....	<b>149</b>
	Hiromi Iwahashi	
<b>10</b>	<b>Lipid Metabolism in Myotonic Dystrophy</b> .....	<b>161</b>
	Hiroto Takada	
<b>11</b>	<b>Dysphagia in Myotonic Dystrophy</b> .....	<b>171</b>
	Sonoko Nozaki	

**12 Disease Modeling and Drug Development with DM1 Patient-Derived iPS Cells** ..... 189  
Toshiyuki Araki, Masayoshi Kamon, and Hidetoshi Sakurai

**13 Therapeutic Development in Myotonic Dystrophy** ..... 203  
Masayuki Nakamori